Dhanvantri Jeevan Rekha Ltd.
Snapshot View

View in App

Prices View details

10.62 ▼0%

14 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.djrl.org
Financial Indicators
Market Cap 4.35 Cr.
Earnings per share (EPS) -3.46 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 202.43 Trailing Twelve Months Ending 2021-03
Book Value / Share 21.93 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.48 Calculated using Price: 10.62
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.41 Cr. 4,098,400 Shares
FaceValue 10
Company Profile

Dhanvantri Jeevan Rekha, incorporated on June 11, 1993 is a multi speciality hospital providing reliable diagnostic and therapeutical services. We lay great emphasis on providing good nursing care and clean environment. Dhanvantri hospital has been on the fore front of providing state of art equipment and services in western UP since 1994.

It offers diagnostic and therapeutic facilities in all specialities, well equipped multidisciplinary intensive care units and cashless hospitalization for accredited patients.

The company is basically engaged in offering different medical facilities like Cardiac Care, Endourology, Gastroenterology, Neuro Surgery, Neurology, Anestheslogy and Orthopedic Surgery.

The company was incorporated as a Public Limited Company with the Registrar of Companies in Uttar Pradesh with the main object of providing diagnostic and therapeutic services including Magnetic Resonance Imaging  (MRI). The company obtained certificate for commencement of business on August 2, 1993. The company was incorporated  with an authorized capital of Rs. 200 Lacs which was subsequently increased to Rs. 500 Lacs from time to time.

In the month of October 1993 the company acquired a constructed building at 1, Saket, Meerut for establishing the Diagnostic Centre. The renovation of the site has already been completed. Diagnostic equipments in the Urology and Cardiology Sections have already been installed and are in operation. The company has acquired the adjacent plot in 2004 on which the future expansion plan is expected to commence shortly.

Services offered by the company:

  • Female Urology
  • Impotency
  • Infertility
  • Lithotripsy
  • Paediatric Urology
  • Cystometrogram
  • Uroflowmetry
  • Uro Oncology 
  • Uro Lithiasis
  • Stricture Urethra
  • Renal Transplant & Dialysis

Future plans :

  • A 100 bedded new wing
  • 30 bedded ICU.
  • Multislice spiral CT scan. 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
1 Month
+39.55%
3 Month
+63.89%
6 Month
+26.43%
1 Year
+61.40%
2 Year
+1.14%
5 Year
-60.74%

Ratios View Details

9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 8.41 14.85 8.79 14.25 10.75 5.68 7.10 0.44 -2.51
Return on Capital Employed (%) 10.72 17.32 14.04 21.14 16.71 11.79 7.91 1.97 -2.55
Return on Assets (%) 6.23 11.06 6.83 10.82 7.95 3.77 4.46 0.30 -1.78

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 5 6 7 8 9 10 11 11 10
Non Curr. Liab. 0 0 0 1 1 2 3 1 1
Curr. Liab. 2 2 2 2 2 4 3 3 3
Minority Int.
Equity & Liab. 7 8 8 11 13 16 16 15 14
Non Curr. Assets 6 5 5 7 8 13 13 13 12
Curr. Assets 2 2 3 4 4 3 3 3 3
Misc. Exp. not W/O
Total Assets 7 8 8 11 13 16 16 15 14

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 5 6 7 8 9 11 14 17 18
Other Income 0 0 0 0 0 0 0 0 0
Total Income 5 6 8 8 10 12 14 17 18
Total Expenditure -4 -4 -6 -6 -8 -10 -12 -16 -18
PBIDT 1 2 2 2 2 2 2 1 1
Interest 0 0 0 0 0 0 0 0 0
Depreciation -1 -1 -1 0 0 0 -1 -1 -1
Taxation 0 0 0 0 0 0 0 0 0
Exceptional Items
PAT 0 1 1 1 1 1 1 0 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1 1 1 1 1 4 1 1 1
Cash Fr. Inv. -2 0 -1 -1 -1 -4 -1 0 0
Cash Fr. Finan. 0 0 0 0 1 0 -2 0
Net Change 0 0 0 0 0 0 0 -1 1
Cash & Cash Eqvt 0 1 0 0 1 1 1 0 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 19.69 19.69 19.68 19.77 19.77 19.77 19.77 19.77 19.77
Public 80.31 80.31 80.32 80.23 80.23 80.23 80.23 80.23 80.23
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 08 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation 201 please find the enclosed herewith copy of the certificate dated 05th July 2021 received from M/s Beetal Financial & Computer services (P) Ltd. the Registrar and Share Transfer Agent of the Company for the Quarter ended 30th June 2021
Thu, 08 Jul 2021
Shareholding for the Period Ended June 30 2021
Dhanvantri Jeevan Rekha Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Thu, 08 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Ritika Bhandari
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

No Scans Found

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,551.74 785.85 +0.0%
Divi's Laboratories Ltd. 130,702.13 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,575.04 4,783.30 +0.2%
Cipla Ltd. 76,243.85 945.20 +0.6%
Cadila Healthcare Ltd. 59,868.47 584.80 -0.5%
Piramal Enterprises Ltd. 59,065.41 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. 58,599.44 4,075.50 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.41 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.87 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.80 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.70 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.06 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 44.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 389.73 4,075.50 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.06 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.45 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.17 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.61 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.73 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.75 4,075.50 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 32.07 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%